SANTEN PHARMACEUTICAL CO.,LTD. Logo

SANTEN PHARMACEUTICAL CO.,LTD.

A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.

4536 | T

Overview

Corporate Details

ISIN(s):
JP3336000009
LEI:
Country:
Japan
Address:
大阪市北区大深町4番20号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santen Pharmaceutical Co., Ltd. is a global pharmaceutical company specializing in ophthalmology. The company engages in the research, development, manufacturing, sales, and marketing of pharmaceutical products and medical devices dedicated to eye health. Its portfolio addresses a wide range of ocular conditions, including glaucoma, dry eye, and infections. Serving patients, consumers, and medical professionals, Santen operates in over 60 countries and regions worldwide, guided by its vision of contributing to "Happiness with Vision" for people globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 07:02
Registration Form
確認書
Japanese 8.7 KB
2025-11-10 07:01
Interim Report
半期報告書-第114期(2025/04/01-2026/03/31)
Japanese 366.6 KB
2025-10-15 03:28
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.2 KB
2025-09-12 04:58
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.9 KB
2025-08-13 03:24
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.8 KB
2025-07-15 04:38
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.2 KB
2025-06-25 04:08
Post-Annual General Meeting Information
臨時報告書
Japanese 26.5 KB
2025-06-24 09:22
Regulatory News Service
臨時報告書
Japanese 32.1 KB
2025-06-23 08:29
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-23 08:28
Registration Form
確認書
Japanese 8.5 KB
2025-06-23 08:27
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 2.2 MB
2025-06-13 04:35
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2025-04-15 06:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB
2025-03-13 03:29
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.8 KB
2025-02-14 02:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.3 KB

Automate Your Workflow. Get a real-time feed of all SANTEN PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SANTEN PHARMACEUTICAL CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SANTEN PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
ARGENX SE Logo
Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.
United States of America ARGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.